Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
BDX • Stock • Health Care / Health Care Equipment
Current Price
$176.80
-0.71%
Provider quote snapshot • As of 2026-10-02T20:00:00.000Z
Back to stock pageCross-Horizon Read
BDX's evidence points supportive across the available windows.
Generated 2026-10-05T10:50:00.000Z • Evidence 1ed54724
Price Data
A quote snapshot is available, but historical price data is not connected yet.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads bullish.
Supporting articles
4
Opposing articles
2
Neutral articles
9
Confidence basis
Supporting evidence
• Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh
• Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks
• Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance
• Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
Opposing evidence
• BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study
• Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views
Catalysts
• Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks
• Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
• Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance
• Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships
• Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views
Risks
• Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks
• Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance
• Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (4) grows relative to opposing evidence (2) in this window.
Weakens if
• Opposing evidence (2) grows relative to supporting evidence (4) in this window.
Showing 8 of 15 sources
Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends
Yahoo • 2026-08-22 • Mixed
Open via Finnhub →Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh
Yahoo • 2026-08-21 • Bullish
Open via Finnhub →Becton Dickinson (BDX) Stock Could Be A Bargain On Cash Flow But Full On Broader Checks
Yahoo • 2026-08-21 • Bullish
Open via Finnhub →BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study
Yahoo • 2026-08-20 • Bearish
Open via Finnhub →Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
Yahoo • 2026-08-13 • Neutral
Open via Finnhub →Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance
Yahoo • 2026-08-10 • Bullish
Open via Finnhub →Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships
Yahoo • 2026-08-09 • Bullish
Open via Finnhub →Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views
Yahoo • 2026-08-09 • Bearish
Open via Finnhub →